ADICET BIO INC (ACET) Stock News

USA - Nasdaq - NASDAQ:ACET - US0070021086 - Common Stock

0.63 USD

+0.03 (+4.6%)

Last: 11/24/2025, 12:25:46 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ACET Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Adicet Bio, Inc.

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

20 days ago - By: Benzinga - Mentions: RIGL TEM AKTX NBP ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

24 days ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

4 months ago - By: The Motley Fool

Adicet Bio (ACET) Q2 Loss Widens 3%

a month ago - By: Adicet Bio, Inc.

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

2 months ago - By: Benzinga

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

2 months ago - By: Adicet Bio, Inc.

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

2 months ago - By: Adicet Bio, Inc.

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

2 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research

Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

3 months ago - By: Adicet Bio, Inc.

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Zacks Investment Research

Adicet Bio (ACET) Upgraded to Buy: Here's Why

4 months ago - By: Yahoo Finance - Mentions: MXCT

MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio

4 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

4 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

4 months ago - By: Adicet Bio, Inc.

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

6 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

7 months ago - By: Zacks Investment Research

Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

7 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

7 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

7 months ago - By: Adicet Bio, Inc.

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

7 months ago - By: Adicet Bio, Inc.

Adicet Bio Appoints Michael Grissinger to the Board of Directors

8 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

9 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

9 months ago - By: Adicet Bio, Inc.

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

9 months ago - By: Adicet Bio, Inc.

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

10 months ago - By: Stocktwits - Mentions: SHPH LPTX NXTC KURA

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

10 months ago - By: Adicet Bio, Inc.

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

10 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)